2m 2m 2m 2m 2m 2m 2m
BASEL MED (BMGL)
NASDAQ
$0.65-$0.03 (-4.39%)
Price as of Nov 12, 2026 9:07 AM EST- N/AMarket Cap
- -95.93%1-Year Change
- Medical Care FacilitiesIndustry
BASEL MED (BMGL)
$0.65-$0.03 (-4.39%)
Annual
Quarterly
06/30/2026 | 06/30/2025 | ||
|---|---|---|---|
Income Statement | |||
Total Operating Revenue | 12.8M +43.92% | 8.9M N/A | |
Cost of Revenue | N/A N/A | N/A N/A | |
Gross Profit | 12.8M +43.92% | 8.9M N/A | |
Sales and Marketing Expense | 389,106 -19.10% | 480,960 N/A | |
Research and Development Expense | N/A N/A | N/A N/A | |
Depreciation and Amortization Expense | N/A N/A | N/A N/A | |
Total Operating Expenses | N/A N/A | N/A N/A | |
Operating Profit | N/A N/A | N/A N/A | |
Interest Income | N/A N/A | N/A N/A | |
Interest Expense | N/A N/A | N/A N/A | |
Interest Income and Expense and Net | 0 N/A | 0 N/A | |
Total Nonoperating Income and Expense | 710,976 -42.00% | 1.2M N/A | |
Income before Taxes | -1.1M -86.68% | -8.4M N/A | |
Income Taxes | 139,886 +142.63% | -328,165 N/A | |
Extraordinary Items | N/A N/A | N/A N/A | |
Net Income | -1.1M -86.68% | -8.4M N/A | |
Net Income from Continuing Operations Applicable to Common | -1.1M -86.68% | -8.4M N/A | |
Basic EPS and Net Income | -0.61 +35.56% | -0.45 N/A | |
Diluted EPS and Net Income | -0.61 +35.56% | -0.45 N/A | |
Basic Weighted Average Shares | 1.6M -91.58% | 18.8M N/A | |
Diluted Weighted Average Shares | 1.6M -91.58% | 18.8M N/A | |
Balance Sheet | |||
Cash and Cash Equivalents | N/A N/A | N/A N/A | |
Short-Term Investments | N/A N/A | N/A N/A | |
Cash and Cash Equivalents and Short-Term Investments | 0 N/A | 0 N/A | |
Total Current Assets | 9.4M -10.33% | 10.5M N/A | |
Accumulated Depreciation | N/A N/A | N/A N/A | |
Property and Plant and Equipment and Net | N/A N/A | N/A N/A | |
Total Long-Term Assets | 4.4M +3.26% | 4.2M N/A | |
Total Assets | 13.7M -6.41% | 14.7M N/A | |
Income Taxes Payable | N/A N/A | N/A N/A | |
Total Short-Term Debt | 4.1M +144.04% | 1.7M N/A | |
Total Current Liabilities | 7.6M -4.61% | 8.0M N/A | |
Total Long-Term Debt | N/A N/A | N/A N/A | |
Total Long-Term Liabilities | 2.6M +8.16% | 2.4M N/A | |
Total Liabilities | 10.2M -1.64% | 10.4M N/A | |
Retained Earnings | -3.2M +20.52% | -2.7M N/A | |
Total Stockholders Equity | 3.5M -18.01% | 4.3M N/A | |
Total Shares Outstanding | 18.8M N/A | N/A N/A | |
Cash Flow | |||
Cash from Operating Activities | -531,956 -83.27% | -3.2M N/A | |
Capital Expenditures | N/A N/A | N/A N/A | |
Cash from Investing Activities | -80,506 -99.06% | -8.6M N/A | |
Dividends Paid | N/A N/A | N/A N/A | |
Cash from Financing Activities | -1.4M -110.58% | 13.0M N/A | |
Financials Ratio | |||
Gross Margin | N/A N/A | N/A N/A | |
Operating Margin | N/A N/A | N/A N/A | |
Return on Assets | -7.83% N/A | N/A N/A | |
Return on Equity | -28.62% N/A | N/A N/A | |
Revenue Growth | 43.92% N/A | N/A N/A | |
Current Ratio | 1.23 N/A | N/A N/A | |
Cash Ratio | N/A N/A | N/A N/A | |
Debt-to-Equity Ratio | N/A N/A | N/A N/A | |
Debt-to-Assets Ratio | N/A N/A | N/A N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow